ValueEdge

“One of the learnings that I could have, and that was again, hindsight was that maybe part of the payment could be made in cash or part of the payment could have been made in you know, more like a stock component, which comes upfront. That allows us to also par…”

“They were not acquiring us for the revenue, right? I think they were acquiring us for the capability in life sciences. They had a large life sciences practice with one client with, they had like seven, 800 people with that one client where they had built an ou…”

“And the, when we saw the shareholders, the first draft that came from, they was Shardola Merchant, WNS. We kind of had a heart attack, right? Because they had things like, you know, if somebody leaves, then they'll have a claw back and so on. They had identifi…”

“I recall we identified something like, fuck the possible you know, acquirers. And you know, given that we were in the life sciences domain analytics domain, I mean, that, 40 is the reasonable number. And then they ran the sort of teaser, right? And I remember …”

“It was a twenty million dollar exit with, you know, 17.5 million cash upfront and then the balance in RSUs and all the cash 70% was you know, paid on day one and the 30% was paid over three years.”

“At the time of exit you know, we had a couple of million-dollar-plus clients. There was Roche, there was Merck, there was Bayer you know, blue-chip clients. And it was about a 150 people team with offices in the US in Europe, in Frankfurt and in Switzerland. S…”

“In the short journey of Value Edge of seven, eight years, Roche became a two million dollar business. And in, in a company which eventually had a business size of around six and a half, seven million dollars.”